AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24129852 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 0
Study 21435141 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg dapagliflozin fed (high-fat meal)
Number of subjects: 14
Study 21435141 — intervention group
Group type: COMPARATOR
Intervention: 10-mg dapagliflozin fasted
Number of subjects: 14
Study 19455069 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month cessation
Number of subjects: 1535
Study 19455069 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month cessation
Number of subjects: 1535
Study 19455069 — intervention group
Group type: COMPARATOR
Intervention: No cessation
Number of subjects: 1535
Study 19455069 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-plus-progestin users
Number of subjects: 1535
Study 16827738 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutment with cemented implant-supported single-tooth crown
Number of subjects: 20
Study 16827738 — intervention group
Group type: COMPARATOR
Intervention: Gold-alloy abutment with cemented implant-supported single-tooth crown
Number of subjects: 20
Study 12723857 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy (S), nonsteroid anti-inflammatory with orphenadrine citrate (O), and benzodiazepine (B)
Number of subjects: 21
Study 10786738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microg i.v. (Group F)
Number of subjects: 80
Study 10786738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg/ml for infiltration of trocar sites (Group B)
Number of subjects: 80
Study 10786738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg i.v. (Group T)
Number of subjects: 80
Study 10786738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 80
Study 9453906 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal (TAPP) approach
Number of subjects: 0
Study 9453906 — intervention group
Group type: COMPARATOR
Intervention: Open approach (Shouldice) without mesh implantation
Number of subjects: 0
Study 9453906 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic preperitoneal (TEP) approach
Number of subjects: 0
Study 8440094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (up-titrated from 20 mg to 80 mg/day during the first 16 weeks)
Number of subjects: 0
Study 8440094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3527514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripamide 10 mg
Number of subjects: 24
Study 3527514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripamide 25 mg
Number of subjects: 24
Study 3527514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripamide 50 mg
Number of subjects: 24
Study 3527514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripamide 100 mg
Number of subjects: 24
Study 3527514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31325546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural hospice family caregivers
Number of subjects: 196
Study 31325546 — intervention group
Group type: COMPARATOR
Intervention: Urban hospice family caregivers
Number of subjects: 196
Study 29037786 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR) session
Number of subjects: 64
Study 29037786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 25502581 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg orally daily for 12 months)
Number of subjects: 130
Study 25502581 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (in vitro treatment)
Number of subjects: 130
Study 25502581 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg orally daily for 12 months)
Number of subjects: 130
Study 25502581 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (in vitro treatment)
Number of subjects: 130
Study 23967636 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 200
Study 23967636 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 200
Study 21215439 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 279
Study 21215439 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 279
Study 18268422 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy applied by nasal prongs
Number of subjects: 18
Study 18268422 — intervention group
Group type: COMPARATOR
Intervention: Air delivered by nasal prongs
Number of subjects: 18
Study 16809237 — intervention group
Group type: EXPERIMENTAL
Intervention: CREON2000 units
Number of subjects: 19
Study 16809237 — intervention group
Group type: COMPARATOR
Intervention: Placebo units
Number of subjects: 19
Study 14666022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 85
Study 14666022 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 85
Study 10695905 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid bolus regimen (7.5 microg x kg(‐1) fentanyl, 70% N2O, with 2.5 microg x kg(‐1) supplements as needed)
Number of subjects: 180
Study 10695905 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid infusion (Alfentanil 50 microg x kg(‐1) bolus, 1‐1.5 microg x kg(‐1) x min(‐1) infusion, 70% N2O)
Number of subjects: 180
Study 10695905 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.3% (Fentanyl 1 microg x kg(‐1), 70% N2O, isoflurane 0.3% expired)
Number of subjects: 180
Study 10695905 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.7% (Fentanyl 1 microg x kg(‐1), 70% N2O, isoflurane 0.7% expired)
Number of subjects: 180
Study 10695905 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide with bolus supplementation
Number of subjects: 180
Study 9082104 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cefazolin (group 2)
Number of subjects: 189
Study 9082104 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefazolin (group 1)
Number of subjects: 189
Study 1417231 — intervention group
Group type: EXPERIMENTAL
Intervention: Capiox (membrane oxygenator)
Number of subjects: 51
Study 1417231 — intervention group
Group type: EXPERIMENTAL
Intervention: Polystan (bubbler)
Number of subjects: 51
Study 1417231 — intervention group
Group type: EXPERIMENTAL
Intervention: William Harvey (bubbler)
Number of subjects: 51
Study 6362715 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 80
Study 6362715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 6362715 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 80
Study 30857952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total knee arthroplasty
Number of subjects: 85
Study 30857952 — intervention group
Group type: COMPARATOR
Intervention: Cementless total knee arthroplasty
Number of subjects: 85
Study 30429144 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero-balance goal-directed fluid therapy (GDT)
Number of subjects: 310
Study 30429144 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 310
Study 26272051 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride (low-dose 0.5 mg/day)
Number of subjects: 32
Study 26272051 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride (high-dose 2.5 mg/day)
Number of subjects: 32
Study 26272051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24645970 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mJ, density 10%
Number of subjects: 20
Study 24645970 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mJ, density 20%
Number of subjects: 20
Study 24645970 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 10 mJ, density 10%
Number of subjects: 20
Study 24645970 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 20 mJ, density 10%
Number of subjects: 20
Study 22494776 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific movement control exercises (SMCE)
Number of subjects: 0
Study 22494776 — intervention group
Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 0
Study 19490746 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial family intervention, individual counselling and standard treatment
Number of subjects: 50
Study 19490746 — intervention group
Group type: COMPARATOR
Intervention: Individual counselling and standard treatment
Number of subjects: 50
Study 17295567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg) plus group behavioral quit‐smoking treatment for 12 weeks
Number of subjects: 247
Study 17295567 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus group behavioral quit‐smoking treatment for 12 weeks
Number of subjects: 247
Study 15591164 — intervention group
Group type: EXPERIMENTAL
Intervention: R207910
Number of subjects: 0
Study 15591164 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid and Rifampin
Number of subjects: 0
Study 12501741 — intervention group
Group type: EXPERIMENTAL
Intervention: APN intervention
Number of subjects: 0
Study 11350324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine field block administered after induction but before surgery
Number of subjects: 40
Study 11350324 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine field block administered after surgery but before the end of anaesthesia
Number of subjects: 40
Study 9646424 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy
Number of subjects: 0
Study 9646424 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8159506 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSR feeding method
Number of subjects: 69
Study 8159506 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 3131041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG) at doses ranging from 10 to 120 micrograms/min (mean = 52 +/- 33 micrograms/min)
Number of subjects: 10
Study 3131041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 10
Study 3131041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3131041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual NTG (0.4 mg) as a positive control
Number of subjects: 10
Study 30261883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing desks in intervention schools (10 schools: 5 primary, 5 secondary) for 6 months.
Number of subjects: 311
Study 30261883 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and interviews with pupils and teachers regarding standing desks.
Number of subjects: 311
Study 30261883 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative process evaluation data from intervention group.
Number of subjects: 311
Study 30261883 — intervention group
Group type: COMPARATOR
Intervention: Control schools (9 schools: 5 primary, 4 secondary).
Number of subjects: 311
Study 28363702 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for physiotherapists (8 hours)
Number of subjects: 255
Study 28363702 — intervention group
Group type: COMPARATOR
Intervention: Control group with physiotherapist completing a 1-hour workshop on evidence-based chronic low back pain management
Number of subjects: 255
Study 28363702 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for physiotherapists
Number of subjects: 255
Study 25750876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (simultaneous balance and cognitive training using the BioRescue)
Number of subjects: 20
Study 25750876 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional balance training)
Number of subjects: 20
Study 24534303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thoracic paravertebral block
Number of subjects: 40
Study 21160312 — intervention group
Group type: EXPERIMENTAL
Intervention: Defunctioning stomas (n = 116)
Number of subjects: 234
Study 21160312 — intervention group
Group type: COMPARATOR
Intervention: No defunctioning stomas (n = 118)
Number of subjects: 234
Study 18240348 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy plus ecabet sodium (group B)
Number of subjects: 257
Study 18240348 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (group A)
Number of subjects: 257
Study 16999353 — intervention group
Group type: EXPERIMENTAL
Intervention: Edgewise appliance combined with flat bite plate treatment
Number of subjects: 65
Study 16999353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 65
Study 12742208 — intervention group
Group type: EXPERIMENTAL
Intervention: Open tension-free inguinal hernia repair
Number of subjects: 2165
Study 12742208 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic tension-free inguinal hernia repair
Number of subjects: 2165
Study 10816930 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral guidelines for orthodontic treatment
Number of subjects: 0
Study 10816930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no referral guidelines)
Number of subjects: 0
Study 8784319 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 20
Study 8784319 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 20
Study 1351804 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg tramadol hydrochloride
Number of subjects: 161
Study 1351804 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg tramadol hydrochloride
Number of subjects: 161
Study 1351804 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen plus propoxyphene napsylate (650 mg + 100 mg)
Number of subjects: 161
Study 1351804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 31398932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention based on diet and physical activity
Number of subjects: 20
Study 31398932 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (control)
Number of subjects: 20
Study 30246748 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)2)
Number of subjects: 34
Study 30246748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) gel
Number of subjects: 34
Study 30246748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metronidazole gel
Number of subjects: 34
Study 26403199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 5107
Study 26403199 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5107
Study 24113254 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate 250 mg weekly
Number of subjects: 315
Study 24113254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 24113254 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 supplementation
Number of subjects: 315
Study 22857778 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture with optimistic communication
Number of subjects: 311
Study 22857778 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with neutral expectations
Number of subjects: 311
Study 20145342 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) + statin
Number of subjects: 0
Study 20145342 — intervention group
Group type: COMPARATOR
Intervention: Statin alone
Number of subjects: 0
Study 20145342 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete adherence
Number of subjects: 0
Study 18357861 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC algorithm
Number of subjects: 20
Study 18357861 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 20
Study 18357861 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 20
Study 16236835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg/d
Number of subjects: 863
Study 16236835 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/d
Number of subjects: 863
Study 16236835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 863
Study 16236835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC), 100/50 microg bid for 4 weeks
Number of subjects: 863
Study 12109769 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic moves available in Experiment 1
Number of subjects: 0
Study 12109769 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to capitalize on visual hints in Experiment 2
Number of subjects: 0
Study 10534607 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 5 mg
Number of subjects: 131
Study 10534607 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 20 mg
Number of subjects: 131
Study 10534607 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine 10 mg
Number of subjects: 131
Study 10534607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 5 mg, 10 mg, 20 mg
Number of subjects: 131
Study 10534607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 7793652 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg oral)
Number of subjects: 21
Study 7793652 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 21
Study 2108816 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPM (cyclophosphamide, Adriamycin, cisplatin, mitomycin C)
Number of subjects: 136
Study 2108816 — intervention group
Group type: COMPARATOR
Intervention: MCT (mitomycin C, cytosine arabinoside, tegafur)
Number of subjects: 136
Study 2108816 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPM
Number of subjects: 136
Study 2108816 — intervention group
Group type: COMPARATOR
Intervention: MCT
Number of subjects: 136
Study 6158404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective auditory attention to high frequency tones
Number of subjects: 12
Study 6158404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective auditory attention to low frequency tones
Number of subjects: 12
Study 6158404 — intervention group
Group type: COMPARATOR
Intervention: Unattended shorter tones
Number of subjects: 12
Study 31427870 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min core muscle exercise with inspiratory loaded breathing after 11-min passive recovery
Number of subjects: 9
Study 31427870 — intervention group
Group type: COMPARATOR
Intervention: 15-min passive recovery
Number of subjects: 9
Study 31427870 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior thigh muscle perfusion assessed by near-infrared spectroscopy following the re-warm-up exercises
Number of subjects: 9
Study 28829934 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS (tribochemical silica coating via air‐abrasion with 30‐μm silica‐coated alumina particles)
Number of subjects: 100
Study 28829934 — intervention group
Group type: EXPERIMENTAL
Intervention: NANO (silica nanofilm deposition via magnetron sputtering)
Number of subjects: 100
Study 28829934 — intervention group
Group type: EXPERIMENTAL
Intervention: GHF1 (glaze application + HF for 1 minute)
Number of subjects: 100
Study 28829934 — intervention group
Group type: EXPERIMENTAL
Intervention: GHF15 (glaze application + HF for 15 minutes)
Number of subjects: 100
Study 28829934 — intervention group
Group type: EXPERIMENTAL
Intervention: GHF5 (glaze application + HF for 5 minutes)
Number of subjects: 100
Study 25742472 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (CB)
Number of subjects: 280
Study 25742472 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (C)
Number of subjects: 280
Study 25742472 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab plus mitomycin C (CBM)
Number of subjects: 280
Study 23880010 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-laboratory-based CVD risk score
Number of subjects: 14772
Study 21849186 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Number of subjects: 5379
Study 21849186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5379
Study 19552227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-adapted dental environment (SADE)
Number of subjects: 16
Study 17343309 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention (specifics not provided)
Number of subjects: 0
Study 17343309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublining CD68+ macrophages
Number of subjects: 0
Study 15541162 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% NaF varnish
Number of subjects: 16
Study 15541162 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF rinse
Number of subjects: 16
Study 11295651 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sensitivities to environmental factors
Number of subjects: 1041
Study 11295651 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sensitivities to animal exposure
Number of subjects: 1041
Study 11295651 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental modification of homes
Number of subjects: 1041
Study 11295651 — intervention group
Group type: COMPARATOR
Intervention: Exposure to parental cigarette smoking
Number of subjects: 1041
Study 11295651 — intervention group
Group type: COMPARATOR
Intervention: Exposure to house dust
Number of subjects: 1041
Study 11295651 — intervention group
Group type: COMPARATOR
Intervention: Exposure to damp and musty areas
Number of subjects: 1041
Study 9560064 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 75 mg (TDZ)
Number of subjects: 12
Study 9560064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9560064 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (0, 25, 50 mg)
Number of subjects: 12
Study 9560064 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (75 mg)
Number of subjects: 12
Study 7889948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 139
Study 7889948 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 139
Study 17171865 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA applied at least 90 minutes prior to cannulation
Number of subjects: 3